1stOncology™: Cancer Intelligence Service – Page 11650 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Ultragenyx to Present at Upcoming Investor Conferences

On May 28, 2020 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, reported that it will hold virtual presentations at the following upcoming investor conferences (Press release, Ultragenyx Pharmaceutical, MAY 28, 2020, View Source [SID1234558609]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Shalini Sharp, the company’s Chief Financial Officer, will hold a virtual presentation at the Jefferies Healthcare Conference on Wednesday, June 3, 2020 at 2 PM ET.
Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will hold a virtual presentation at the Goldman Sachs 41ST Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 3:50 PM ET.
The live and archived webcast of these presentations will be accessible from the company’s website at View Source Replays of the webcasts will be available for 90 days.

Pieris Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference

On May 28, 2020 Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer, and other indications, reported that management will present at the Jefferies 2020 Virtual Healthcare Conference on Thursday, June 4, 2020 at 3:30 PM EDT (Press release, Pieris Pharmaceuticals, MAY 28, 2020, View Source [SID1234558608]). A webcast of the company’s presentation will be available at this link.

IntelGenx Announces Intention to Issue Shares in Payment of Principal on Outstanding Debentures, and Meeting of Debentureholders

On May 28, 2020 IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) ("IntelGenx" or the "Corporation") reported that it intends to issue shares of common stock ("Common Shares") of the Corporation in payment of the outstanding $7,577,000 aggregate principal amount of the Corporation’s 8.00% convertible unsecured subordinated debentures due June 30, 2020 (the "Debentures") (Press release, IntelGenx, MAY 28, 2020, View Source [SID1234558607]).

Under the terms of the trust indenture governing the Debentures (the "Indenture"), the Corporation has the option to satisfy its obligation to repay all or any portion of the principal amount of the Debentures outstanding by issuing and delivering Common Shares at a deemed price of 95% of the current market price (as defined in the Indenture) at the maturity date, subject to customary conditions set forth in the Indenture. The issuance of the Common Shares in repayment of the principal of the Debentures is subject to the acceptance by the TSX Venture Exchange (the "TSX-V"). The Common Shares issued in payment of interest on the Debentures will be issued pursuant to exemptions from the prospectus requirements of applicable securities laws.

The Corporation also announced today that a meeting of the holders of the Debentures (the "Meeting") will be held on Thursday, June 25, 2020. Debentureholders as of the record date of May 28, 2020 will receive a notice and information circular in respect of the Meeting and information on how to attend the Meeting will be provided on the Corporation’s website in due course. As previously announced, the Corporation is proposing to amend the terms of the Debentures to extend the maturity date from June 30, 2020 to June 30, 2022 and reduce the conversion price from $1.35 to $0.50 (together, the "Proposed Amendments"). The Proposed Amendments, which have been conditionally approved by the TSX-V, remain subject to approval by the holders of not less than 66 2/3% of the outstanding principal amount of the Debentures represented at the Meeting. If debentureholder approval is obtained, the Corporation intends to proceed with the Proposed Amendments, including the extension of the maturity date, such that the intended repayment of principal in Common Shares on June 30, 2020 indicated above would no longer be required and would not occur.

The Debentures are listed on the TSX-V under the symbol "IGX.DB".

Halozyme To Present At Upcoming Virtual Investor Conferences

On May 28, 2020 Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported that Dr. Helen Torley, president and chief executive officer, will be participating in the following investor conferences (Press release, Halozyme, MAY 28, 2020, View Source [SID1234558606]):

Jefferies Virtual Healthcare Conference at 10:00 a.m. ET / 7:00 a.m. PT on Thursday, June 4, 2020
Goldman Sachs 41st Annual Healthcare Conference at 4:40 p.m. ET / 1:40 p.m. PT on Wednesday, June 10, 2020
A live webcast of each event can be accessed through the "Investors" section of Halozyme’s website (www.halozyme.com), and an archive will be made available for 90 days following each event. To access a live webcast, please visit Halozyme’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises

On May 28, 2020 Genprex, Inc. ("Genprex" or the "Company") (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, reported that warrants to purchase approximately 5.4 million shares of common stock issued in connection with capital raises in May 2018 and November 2019 with two institutional investors have been exercised at a price of $0.46 per share, resulting in cash proceeds of approximately $2.5 million to the Company (Press release, Genprex, MAY 28, 2020, View Source [SID1234558605]). The warrants were exercised on or about May 22, 2020, the first day they became exercisable under the terms of their respective agreements.

The exercised warrants include all warrants that have been issued to investors in the Company’s public financings to date and represent approximately 70% of the Company’s overall outstanding warrants. Warrants remaining after the exercise carry a weighted average exercise price of approximately $3.93. Genprex believes that the elimination of the majority of its outstanding warrants is a significant milestone for the Company in that it provides a dramatically simplified capital structure.

In 2020, Genprex has raised gross proceeds of $25.5 million in two registered direct offerings, both priced at the market, with no warrants issued. The additional capital from these recent warrant excercises brings the equity capital raised during 2020 for advancing the Company’s research and development programs and other corporate initiatives, which could include strategic transactions, to roughly $28 million.

With the Company’s significantly strengthened balance sheet (the warrant exercise proceeds added to the more than $23 million in cash on the Company’s balance sheet as of March 31, 2020), Genprex believes it is in a strong position to pursue its planned clinical trial of its lead gene therapy drug candidate, Oncoprex immunogene therapy, combined with targeted therapy Tagrisso (marketed by AstraZeneca) in non-small cell lung cancer (NSCLC) patients whose tumors progressed on Tagrisso, for which the Company was granted United States FDA Fast Track Designation in January 2020; and a planned clinical trial of Oncoprex combined with Keytruda (marketed by Merck) for late stage NSCLC.